Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer

Clinical Breast Cancer

Volumn 16, Issue 5, 2016, Pages 335-343

  Tang, Yuan ^a   Wang, Yue ^b   Kiani, Mohammad F ^a   Wang, Bin ^a,c  

^a Temple University   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c WIDENER UNIVERSITY   (United States)

Author keywords

Clinical trials; Endocrine therapy; Pathways; Treatment strategies; Triple negative breast cancer

Indexed keywords

ABC TRANSPORTER SUBFAMILY B; BREAST CANCER RESISTANCE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; MULTIDRUG RESISTANCE RELATED PROTEIN; PROTEIN; UNCLASSIFIED DRUG; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; PROGESTERONE RECEPTOR;

BREAST CANCER; CLINICAL FEATURE; DRUG RESISTANCE; HUMAN; REVIEW; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; CLASSIFICATION; CLINICAL TRIAL (TOPIC); FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; P-GLYCOPROTEINS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 84971602948     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2016.05.012     Document Type: Review

References (124)

1. American Cancer Society. What are the key statistics about breast cancer? Available at: http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics. Accessed: February 4, 2015.
2. Giessrigl, B., Schmidt, W.M., Kalipciyan, M., et al. Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer 109 (2013), 2751–2762.
3. Marquette, C., Nabell, L., Chemotherapy-resistant metastatic breast cancer. Curr Treat Options Oncol 13 (2012), 263–275.
4. Tomao, F., Papa, A., Zaccarelli, E., et al. Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther 8 (2015), 177–193.
5. Marusyk, A., Polyak, K., Tumor heterogeneity: causes and consequences. Biochim Biophys Acta, 1805, 2010, 105.
6. Sorlie, T., Perou, C.M., Tibshirani, R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001), 10869–10874.
7. Sorlie, T., Tibshirani, R., Parker, J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 (2003), 8418–8423.
8. Brenton, J.D., Carey, L.A., Ahmed, A.A., Caldas, C., Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 23 (2005), 7350–7360.
9. Rakha, E.A., El-Sayed, M.E., Reis-Filho, J.S., Ellis, I.O., Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology 52 (2008), 67–81.
10. Parker, J.S., Mullins, M., Cheang, M.C., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27 (2009), 1160–1167.
11. Sotiriou, C., Pusztai, L., Gene-expression signatures in breast cancer. N Engl J Med 360 (2009), 790–800.
12. Correa Geyer, F., Reis-Filho, J.S., Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?. Int J Surg Pathol 17 (2009), 285–302.
13. Lehmann, B.D., Bauer, J.A., Chen, X., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121 (2011), 2750–2767.
14. Masuda, H., Baggerly, K.A., Wang, Y., et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19 (2013), 5533–5540.
15. Nagaraj, G., Ellis, M.J., Ma, C.X., The natural history of hormone receptor–positive breast cancer: attempting to decipher an intriguing concept. Oncology (Williston Park) 26 (2012), 696–697 700.
16. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005), 1687–1717.
17. Deroo, B.J., Korach, K.S., Estrogen receptors and human disease. J Clin Invest 116 (2006), 561–570.
18. American Cancer Society. Aromatase inhibitors. Available at: http://www.cancer.org/cancer/breastcancer/moreinformation/medicinestoreducebreastcancer/medicines-to-reduce-breast-cancer-risk-aromatase-inhibitors. Accessed: February 20, 2015.
19. O'Shaughnessy, J., Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10:suppl 3 (2005), 20–29.
20. Mitri, Z., Constantine, T., O'Regan, R., The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract, 2012, 2012, 743193.
21. Rybarova, S., Hodorova, I., Hajdukova, M., et al. Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters. Neoplasma 53 (2006), 128–135.
22. Dent, R., Trudeau, M., Pritchard, K.I., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:15 pt 1 (2007), 4429–4434.
23. Anders, C., Carey, L.A., Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22 (2008), 1233–1239.
24. Foulkes, W.D., Smith, I.E., Reis-Filho, J.S., Triple-negative breast cancer. N Engl J Med 363 (2010), 1938–1948.
25. Arnedos, M., Bihan, C., Delaloge, S., Andre, F., Triple-negative breast cancer: are we making headway at least?. Ther Adv Med Oncol 4 (2012), 195–210.
26. Mohammadizadeh, F., Sajadieh, S., Sajjadieh, H., Kasaei, Z., Androgen receptor expression and its relationship with clinicopathological parameters in an Iranian population with invasive breast carcinoma. Adv Biomed Res, 3, 2014, 132.
27. Hu, R., Dawood, S., Holmes, M.D., et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 17 (2011), 1867–1874.
28. Musgrove, E.A., Sutherland, R.L., Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9 (2009), 631–643.
29. Bianco, S., Gevry, N., Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms. Transcription 3 (2012), 165–170.
30. Pohlmann, P.R., Mayer, I.A., Mernaugh, R., Resistance to trastuzumab in breast cancer. Clin Cancer Res 15 (2009), 7479–7491.
31. Vu, T., Claret, F.X., Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol, 2, 2012, 62.
32. Chen, K.G., Sikic, B.I., Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 18 (2012), 1863–1869.
33. Clemons, M., Danson, S., Howell, A., Tamoxifen (“Nolvadex”): a review. Cancer Treat Rev 28 (2002), 165–180.
34. Ring, A., Dowsett, M., Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11 (2004), 643–658.
35. Merenbakh-Lamin, K., Ben-Baruch, N., Yeheskel, A., et al. D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 73 (2013), 6856–6864.
36. Nass, N., Kalinski, T., Tamoxifen resistance: from cell culture experiments towards novel biomarkers. Pathol Res Pract 211 (2015), 189–197.
37. Thomas, S., Thurn, K.T., Raha, P., Chen, S., Munster, P.N., Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS One, 8, 2013, e68973.
38. Robinson, D.R., Wu, Y.M., Vats, P., et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45 (2013), 1446–1451.
39. Li, S., Shen, D., Shao, J., et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer–derived xenografts. Cell Rep 4 (2013), 1116–1130.
40. Li, J., Yen, C., Liaw, D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997), 1943–1947.
41. Miller, T.W., Perez-Torres, M., Narasanna, A., et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 69 (2009), 4192–4201.
42. Raha, P., Thomas, S., Munster, P.N., Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics 3 (2011), 451–470.
43. Baselga, J., Campone, M., Piccart, M., et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med 366 (2012), 520–529.
44. Bachelot, T., Bourgier, C., Cropet, C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30 (2012), 2718–2724.
45. Beaver, J.A., Park, B.H., The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor–positive advanced breast cancer. Future Oncol 8 (2012), 651–657.
46. Turner, N.C., Ro, J., Andre, F., et al. Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med 373 (2015), 209–219.
47. Cristofanilli, M., Turner, N.C., Bondarenko, I., et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17 (2016), 425–439.
48. Yardley, D.A., Ismail-Khan, R.R., Melichar, B., et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 31 (2013), 2128–2135.
49. +, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer—part 1 results. Paper presented at: San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX.
50. Hudis, C.A., Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357 (2007), 39–51.
51. Nagy, P., Friedlander, E., Tanner, M., et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65 (2005), 473–482.
52. Palyi-Krekk, Z., Barok, M., Isola, J., Tammi, M., Szollosi, J., Nagy, P., Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 43 (2007), 2423–2433.
53. Nahta, R., Esteva, F.J., HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res, 8, 2006, 215.
54. Baselga, J., Gelmon, K.A., Verma, S., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28 (2010), 1138–1144.
55. Saal, L.H., Holm, K., Maurer, M., et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65 (2005), 2554–2559.
56. Andre, F., O'Regan, R., Ozguroglu, M., et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15 (2014), 580–591.
57. Mayer, I., Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. Clin Adv Hematol Oncol 11 (2013), 217–224.
58. Clynes, R.A., Towers, T.L., Presta, L.G., Ravetch, J.V., Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6 (2000), 443–446.
59. Musolino, A., Naldi, N., Bortesi, B., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26 (2008), 1789–1796.
60. Geyer, C.E., Forster, J., Lindquist, D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006), 2733–2743.
61. von Minckwitz, G., Schwedler, K., Schmidt, M., et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 47 (2011), 2273–2281.
62. Slamon, D.J., Leyland-Jones, B., Shak, S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001), 783–792.
63. Tacca, O., Penault-Llorca, F., Abrial, C., et al. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 12 (2007), 636–643.
64. van de Ven, S., Smit, V.T., Dekker, T.J., Nortier, J.W., Kroep, J.R., Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 37 (2011), 422–430.
65. Hirata, T., Shimizu, C., Yonemori, K., et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer 101 (2009), 1529–1536.
66. Harbeck, N., Huang, C.S., Hurvitz, S., et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol 17 (2016), 357–366.
67. Gelmon, K.A., Boyle, F.M., Kaufman, B., et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2–positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol 33 (2015), 1574–1583.
68. Zelnak, A.B., Wisinski, K.B., Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?. Cancer 121 (2015), 17–24.
69. Verma, S., Miles, D., Gianni, L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367 (2012), 1783–1791.
70. LoRusso, P.M., Weiss, D., Guardino, E., Girish, S., Sliwkowski, M.X., Trastuzumab emtansine: a unique antibody–drug conjugate in development for human epidermal growth factor receptor 2–positive cancer. Clin Cancer Res 17 (2011), 6437–6447.
71. Teicher, B.A., Doroshow, J.H., The promise of antibody–drug conjugates. N Engl J Med 367 (2012), 1847–1848.
72. Boyle, P., Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23:suppl 6 (2012), vi7–v12.
73. Hudis, C.A., Gianni, L., Triple-negative breast cancer: an unmet medical need. Oncologist 16:suppl 1 (2011), 1–11.
74. Perez, E.A., Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 114 (2009), 195–201.
75. Wind, N.S., Holen, I., Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int J Breast Cancer, 2011, 2011, 967419.
76. Clarke, R., Leonessa, F., Trock, B., Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol 32(6 suppl 7) (2005), S9–S15.
77. Hutson, J.R., Koren, G., Matthews, S.G., Placental P-glycoprotein and breast cancer resistance protein: influence of polymorphisms on fetal drug exposure and physiology. Placenta 31 (2010), 351–357.
78. Schinkel, A.H., The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8 (1997), 161–170.
79. Rao, V.V., Dahlheimer, J.L., Bardgett, M.E., et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance–associated protein contribute to the blood–cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 96 (1999), 3900–3905.
80. Leonessa, F., Clarke, R., ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10 (2003), 43–73.
81. Tang, Y., Wang, Y., Deosarkar, S., Soroush, F., Kiani, M.F., Wang, B., Fast, stable induction of P-glycoprotein-mediated drug resistance in BT-474 breast cancer cells by stable transfection of ABCB1 gene. Anticancer Res 35 (2015), 2531–2538.
82. Chevillard, S., Lebeau, J., Pouillart, P., et al. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 3:12 pt 1 (1997), 2471–2478.
83. Arnal, M., Franco, N., Fargeot, P., Riedinger, J.M., Brunet-Lecomte, P., Lizard-Nacol, S., Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res Treat 61 (2000), 13–20.
84. Gago, F.E., Tello, O.M., Diblasi, A.M., Ciocca, D.R., Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients. J Steroid Biochem Mol Biol 67 (1998), 431–437.
85. He, L., Hao, C., Lin, B., Wang, Y., Gao, F., P-glycoprotein expression in primary breast cancer. Chin Med Sci J 10 (1995), 12–15.
86. Vtorushin, S.V., Khristenko, K.Y., Zavyalova, M.V., et al. The phenomenon of multi-drug resistance in the treatment of malignant tumors. Exp Oncol 36 (2014), 144–156.
87. Mross, K., Bohn, C., Edler, L., et al. Randomized phase II study of single-agent epirubicin +/− verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society. Ann Oncol 4 (1993), 45–50.
88. Zaman, G.J., Flens, M.J., van Leusden, M.R., et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A 91 (1994), 8822–8826.
89. Breuninger, L.M., Paul, S., Gaughan, K., et al. Expression of multidrug resistance–associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 55 (1995), 5342–5347.
90. Paul, S., Breuninger, L.M., Tew, K.D., et al. ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Proc Natl Acad Sci U S A 93 (1996), 6929–6934.
91. Cole, S.P., Sparks, K.E., Fraser, K., et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54 (1994), 5902–5910.
92. Chang, X.B., A molecular understanding of ATP-dependent solute transport by multidrug resistance–associated protein MRP1. Cancer Metastasis Rev 26 (2007), 15–37.
93. Nooter, K., Westerman, A.M., Flens, M.J., et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1 (1995), 1301–1310.
94. Kruh, G.D., Gaughan, K.T., Godwin, A., Chan, A., Expression pattern of MRP in human tissues and adult solid tumor cell lines. J Natl Cancer Inst 87 (1995), 1256–1258.
95. Huh, H.J., Park, C.J., Jang, S., et al. Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J Korean Med Sci 21 (2006), 253–258.
96. Nooter, K., Brutel de la Riviere, G., Look, M.P., et al. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 76 (1997), 486–493.
97. Borst, P., Evers, R., Kool, M., Wijnholds, J., A family of drug transporters: the multidrug resistance–associated proteins. J Natl Cancer Inst 92 (2000), 1295–1302.
98. Hooijberg, J.H., Broxterman, H.J., Kool, M., et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59 (1999), 2532–2535.
99. Loe, D.W., Almquist, K.C., Deeley, R.G., Cole, S.P., Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271 (1996), 9675–9682.
100. Kerr, I.D., Haider, A.J., Gelissen, I.C., The ABCG family of membrane-associated transporters: you don't have to be big to be mighty. Br J Pharmacol 164 (2011), 1767–1779.
101. Doyle, L.A., Yang, W., Abruzzo, L.V., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95 (1998), 15665–15670.
102. Jani, M., Ambrus, C., Magnan, R., et al. Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics. Arch Toxicol 88 (2014), 1205–1248.
103. Takenaka, K., Morgan, J.A., Scheffer, G.L., et al. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 67 (2007), 6965–6972.
104. Lockhart, A.C., Tirona, R.G., Kim, R.B., Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2 (2003), 685–698.
105. Selever, J., Gu, G., Lewis, M.T., et al. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res 17 (2011), 6510–6521.
106. Wu, A.M., Dalvi, P., Lu, X., et al. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. Mol Pharmacol 83 (2013), 377–388.
107. Kawabata, S., Oka, M., Soda, H., et al. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 9 (2003), 3052–3057.
108. Robey, R.W., To, K.K., Polgar, O., et al. ABCG2: a perspective. Adv Drug Deliv Rev 61 (2009), 3–13.
109. Ni, Z., Bikadi, Z., Rosenberg, M.F., Mao, Q., Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab 11 (2010), 603–617.
110. An, Y., Ongkeko, W.M., ABCG2: the key to chemoresistance in cancer stem cells?. Expert Opin Drug Metab Toxicol 5 (2009), 1529–1542.
111. Marighetti, F., Steggemann, K., Hanl, M., Wiese, M., Synthesis and quantitative structure–activity relationships of selective BCRP inhibitors. ChemMedChem 8 (2013), 125–135.
112. Pusztai, L., Wagner, P., Ibrahim, N., et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104 (2005), 682–691.
113. Warner, E., Hedley, D., Andrulis, I., et al. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 4 (1998), 1451–1457.
114. Falasca, M., Linton, K.J., Investigational ABC transporter inhibitors. Expert Opin Investig Drugs 21 (2012), 657–666.
115. He, M., Wei, M.J., Reversing multidrug resistance by tyrosine kinase inhibitors. Chin J Cancer 31 (2012), 126–133.
116. Lei, T., Srinivasan, S., Tang, Y., et al. Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine 7 (2011), 324–332.
117. Tang, Y., Lei, T., Manchanda, R., et al. Simultaneous delivery of chemotherapeutic and thermal-optical agents to cancer cells by a polymeric (PLGA) nanocarrier: an in vitro study. Pharm Res 27 (2010), 2242–2253.
118. Pattillo, C.B., Venegas, B., Donelson, F.J., et al. Radiation-guided targeting of combretastatin encapsulated immunoliposomes to mammary tumors. Pharm Res 26 (2009), 1093–1100.
119. + advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res 21 (2015), 995–1001.
120. Juric, D., Castel, P., Griffith, M., et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature 518 (2015), 240–244.
121. Dai, C.L., Tiwari, A.K., Wu, C.P., et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68 (2008), 7905–7914.
122. Zhang, D., Pal, A., Bornmann, W.G., et al. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 7 (2008), 1846–1850.
123. Martin, H.L., Smith, L., Tomlinson, D.C., Multidrug-resistant breast cancer: current perspectives. Breast Cancer (Dove Med Press) 6 (2014), 1–13.
124. Wang, B., Rosano, J.M., Cheheltani, R., Achary, M.P., Kiani, M.F., Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opin Drug Deliv 7 (2010), 1159–1173.